MOG, get a rest and stop repeating ur self for f^%k sake...if u know people who work in IB, or use ur typing skills {most probably the only skill u have} and Google some info about BO in pharmaceutical sector, it is mainly based on multiple of market sale potential. As simple as that. Same as banks usually are looked at or valued or analyzed in terms of price to book value (Google book value pls), same goes for bio company and highest expected sales potential, take a multiple of that, discount it, take off debt....etc, divide that by total outstanding shares, u get ur BO price. So if x, y or z value V with their statin as a combo drug at 100 million or 1billion, 10 or 100 billion....their offer will based on that....and if that means a 500 or a 1000% premium, it will easily be sold to their board.
Adding to that, u r seriously out of ur mind and living in ur own world if u think that this will stay at 1 or 2$ before any talks of possible merge or BO....boy, this will run up like crazy and in some cases with a short squeeze it might surpass the Rumored BO price....this is the most I think I ever wrote on ihub, but u seriously need to get a life with ur daily bu*^%#hit
News 
Market Data 
Discover 
